65,437 trials
Deep Vein Thrombosis · Postthrombotic Syndrome
Primary: Number of Participants With Postthrombotic Syndrome as Determined by Villalta Score — 3; 22 Participants — p=<0.0001
Systemic Lupus Erythematosus
Primary: Number of Participants With Adverse Events — 5; 8; 8; 1 Participants
Arhythmia · Atrioventricular Heart-block · Chronic Bundle Branch or Branch Block
Primary: Percentage of Participants Without Complications at MRI Visit + 1 Month. — 100 percentage of paticipants
Influenza
Primary: Area Under the Curve of Virus Load — -2081.98; 18,973.90; 15,944.09; 12,201.14 mins*Eq log10 TCID50/mL
Multiple Myeloma
Primary: Maximum Tolerated Dose of Bendamustine — 80 mg/m^2
PIK3CA-Related Overgrowth Spectrum (PROS) · Growth Disorder · Genetics
Primary: Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA — 7.9; 4.8; 0.71; 6.5 mean percentage change in tissue volume
Malocclusion
Primary: Little's Irregularity Index (LI) at Baseline — 6.11; 6.31; 6.89 mm
Anxiety Disorders
Primary: Change in Anxiety Symptoms — 17.95; 26.2 score on a scale
Hyperkalemia · Resistant Hypertension
Primary: Number of Participants Remaining on Spironolactone at Week 12 — 126; 98 Participants — p=<0.0001
Ventricular Tachycardia
Primary: Time to First Event Requiring ICD Therapy or Incessant VT — 177.2; 148.66 days
High-risk Smoldering Multiple Myeloma
Primary: One-Year Progression-Free Survival (PFS) Rate — 84.5; 74.4 Percentage of participants
Plaque Psoriasis
Primary: Percentage of Participants With Treatment Success at Week 8 — 36.5; 8.13 percentage of participants
Cardiovascular Disease · Acute Coronary Syndrome
Primary: Percentage of Adherent Patients — 590; 4484; 2209; 3633 Participants
Obesity · Diabetes
Primary: Insulin Sensitivity — 4.2; 7.6; 5.4; 10.4 mg/kg/min — p=<0.05
Idiopathic Pulmonary Fibrosis
Primary: Main Study - The Percentage of Collected Auscultation Points — 100; 100 PercentageOfAuscultationPointsCollected